Acadia Healthcare is planning a $50 million expansion at a Philadelphia facility the company bought this summer, according to the Philadelphia Business Journal.
The Franklin company bought the Belmont Center for Comprehensive Treatment from Einstein Healthcare Network for $35 million in June, and initially planned a $10 million investment in the 147-bed facility.
The Philadelphia Business Journal reports the company is planning a $50 million renovation project that includes a six-story medical center.
Schor said the plan is to build a six-story, 178,400 replacement hospital on the property by knocking down an existing structure so the facility can remain open while the work is being done.
Leerink Swann analyst Ana Gupte has launched coverage of Acadia Healthcare with an 'outperform' rating and a $90 price target that gives investors 25 percent of upside from where the shares (Ticker: ACHC) closed on Tuesday. She sees the Franklin-based company beating the Street's consensus EBITDA numbers both this year and next.
Analyst Brian Tanquilut at Jefferies & Co. sees many bright days ahead for Acadia Healthcare investors. Following the company's second-quarter earnings report, he has raised his price target for the stock to $100 from $88. That leaves a lot of upside: Acadia (Ticker: ACHC) closed last week's trading at $81.02 and is to $81.84 this afternoon.
Analyst Paula Torch at Avondale Partners has raised her price target for shares of Acadia Healthcare following the company's second-quarter profit report. The Franklin-based behavioral health care provider is ahead of plan this year in adding beds to its facilities, and new projects will add to the company's ability to grow its top line to $4 billion by 2018. Torch also says margins — especially at the company's United Kingdom and acquired CRC operations — still have upside. That has led her to lift her target for Acadia, which closed Friday (Ticker: ACHC) at $81.78, to $96 from $84. Year to date, they're up more than 30 percent.
Though still highly leveraged, ACHC has consistently demonstrated its ability to generate cash from its current portfolio, and we expect continued solid operating cash flow in 2015 and 2016 to help ACHC execute on deals.
Torch also has taken stock of Community Health Systems' Q2 results and outlook. She's sticking with her 'outperform' rating even though volume and pricing trends "continue to lag peers," mostly due to hospitals previously owned by Health Management Associates. But the factors holding down CHS' valuation — its higher leverage and integration risks, among others — "are starting to mitigate and show signs of improvement," Torch writes. She still sees CHS (Ticker: CYH) climbing to $77 from the $56 and change at which it ended last week.